Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)

Journal of Biomedical Research

Volumn 26, Issue 1, 2012, Pages 8-16

  Mutiso, Joshua Muli ^a,b   Macharia, John Chege ^a   Taracha, Evans ^a   Gicheru, Michael Muita ^b  

^a INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

Author keywords

Adjuvants; Leishmania donovani; Sonicated antigen; Vervet monkey; Visceral leishmaniasis

Indexed keywords

BCG VACCINE; CELL ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; MONOHOSPHORYL LIPID A; MONTANIDE ISA 720; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HAPLORHINI; IMMUNOGENICITY; INOCULATION; LEISHMANIA DONOVANI; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PARASITE; PRIORITY JOURNAL; SKIN INDURATION; VACCINATION; VISCERAL LEISHMANIASIS;

EID: 84857517290     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(12)60002-5     Document Type: Article

References (55)

1. Kaur J, Kaur T, Kaur S Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop 2011, 119:50-56.
2. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, et al. Recombinant Leishmania taren-tolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 2010, 28:53-62.
3. Bhowmick S, Ravindran R, Ali N Gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 2008, 76:1003-1015.
4. Mutiso JM, Macharia JC, Barasa M, Taracha E, Bourdi-chon AJ, Gicheru MM In vitro and in vivo antileish-manial efficacy of a combination therapy of diminazene and artesunate against Leishmania donovani in BALB/c mice. Rev Inst Med Trop Sao Paulo 2011, 53:129-132.
5. World Health Organization Control of leishmaniasis. Sixth World Health Assembly 2007, A60:10.
6. Mutiso JM, Macharia JC, Gicheru MM A review of adjuvants for Leishmania vaccine candidates. J Biomed Res 2010, 24:16-25.
7. Schroeder J, Aebischer T Vaccines for leishmaniasis. Human vaccines 2011, 7:10-15.
8. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Mo-dabber F Leishmaniasis vaccine candidates for development: A global overview. Indian J Med Res 2006, 123:423-438.
9. Afrin F, Ali N Adjuvanticity and protective immunirty elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 1997, 65:2371-2377.
10. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, Kager PA T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 2005, 117:182-191.
11. Wilson ME, Jeronimo SMB, Pearson RD Immunopatho-genesis of infection with the visceralizing Leishmania species. Microbial Pathogen 2005, 38:147-160.
12. Campos-Neto A What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?. Brazilian J Med Biologic Res 2005, 38:979-984.
13. Tripathi P, Singh V, Naik S Immune response to Leish-mania: paradox rather than paradigm. FEMS Immunol Med Microbiol 2007, 51:229-242.
14. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
15. Modabber F Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010, 36(Suppl 1):S58-S61.
16. Gafurov IM Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan. Med Parasitol (Mosk) 1999, 58-59.
17. Modabber F Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995, 89(Suppl 1):S83-S88.
18. Rivier D, Shah R, Bovay P, Mauel J Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Mol Biochem Parasitol 1993, 152:35-46.
19. Gorczynski RM Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cell Immunol 1985, 94:11-20.
20. Kimsey PB, Theodos CM, Mitchen TK, Turco SJ, Titus RG An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect Immun 1993, 61:5205-5213.
21. Silvestre R, Cordeiro-da-Silva A, Santarem N, Vergnes B, Sereno D, Quaissi A SIR2-deficient Leishmania infantum induces a defined IFN-γ/IL-10 pattern that correlates with protection. J Immunol 2007, 179:3161-3170.
22. Titus RG, Gueiros-filho FJ, de Freitas LA, Beverley SM Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A 1995, 92:10267-10271.
23. Veras P, Brodskyn C, Balestieri F, Freitas L, Ramos A, Queiroz A, et al. A dhfrts Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo Cruz 1999, 94:491-496.
24. Silvestre R, Cordeiro-da-Silva A, Quaissi A Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp 2008, 56:123-126.
25. Garg R, Dube A Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 2006, 123:439-454.
26. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 2009, 27:4747-4753.
27. Khalil EA, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, Zijlstra EE, et al. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 2005, 140:349-353.
28. Musa Am, Khalil EA, Mahgoub FA, Elgawi SH, Mo-dabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008, 102:58-63.
29. Mutiso JM, Macharia JC, Mutisya RM, Taracha E Sub-cutaneous immunization against Leishmania major-infection in mice: efficacy of formalin-killed promastigotes combined with adjuvants. Rev Inst Med Trop Sao Paulo 2010, 7:107-116.
30. Misra A, Anuradha D, Bindu S, Preeti S, Srivastava JK, Katiyar JC Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001, 19:3485-3492.
31. Coler RN, Goto Y, Lisa B, Raman V, Reed SG Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immunol 2007, 75:4648-4654.
32. Olobo JO, Reid GDF Mitogenic responses of peripheral blood mononuclear cells of vervet monkeys (Cercop-ithecus aethiops): apparent role of adherent cells. Am J Primatol 1990, 20:31-36.
33. Olobo JO, Reid GDF, Githure JI, Anjili CO IFN-γ and delayed type hypersensitivity are associated with cutaneous leishmaniasis in vervet monkeys following secondary rechallenge with Leishmania major. Scand J Immunol 1992, 36(Suppl 11):S48-S52. (1992).
34. Toledo H, Alberto B, Osvaldo C, Sonia R, Jose L, Felipe R, et al. A phase I clinical trial of a multiepitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001, 19:4328-4336.
35. Masina S, Gicheru MM, Demotz SO, Fasel NJ Protection against cutaneous leishmaniasis in outbred Vervet Monkeys, using a recombinant Histone-1 antigen. J Infect Dis 2003, 188:1250-1257.
36. Oliveira GA, Kristiane W, Calvo-Calle JM, Ruth N, An-nette S, Ashley B, et al. Safety and enhanced immuno-genicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant montanide ISA 720 in a phase I trial. Infect Immun 2005, 73:3585-3597.
37. Vernacchio L, Bernstein H, Pelton S, Allen C, MacDon-ald K, Dunn J, et al. Effect of monophosphoryl lipid A (MPL®) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 2002, 20:3658-3667.
38. Reed SG, Coler RN, Campos-Neto A Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines 2003, 2:239-252.
39. Baldrick P, Richardson D, Elliott G, Wheeler AW Safety evaluation of monophosphoryl lipid A (MPL): An immunostimulatory adjuvant. Regulat Toxicol Pharmacol 2002, 35:398-413.
40. Nateghi RM, Keshavarz H, Khamesipour A Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae. Trop Biomed 2010, 27:89-102.
41. Sasaki S, Tsuji T, Hamajima K, Fukushima J, Ishii N, Kaneko T, et al. Monophosphoryl lipid A enhances both humoral and Cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect Immun 1997, 3520-3528.
42. Macleod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, et al. Vaccine adjuvants aluminium and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A 2011, 108:7914-7919.
43. Gicheru MM, Olobo JO, Kariuki TM, Adhiambo C Vis-ceral leishmaniasis in Vervet Monkeys: Immunological responses during asymptomatic infections. Scand J Immunol 1995, 41:202-208.
44. Nylen S, Guatam S Immunological perspectives of leish-maniasis. Third Annual Immunogenicity Sumit 2011, 2:135-146.
45. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N Immune responsers in kalaazar. Indian J Med Res 2006, 123:245-266.
46. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modab-ber F, Scott P Vervet Monkeys vaccinated with killed Leishmania major parasites and Interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001, 69:245-251.
47. Roberts MTM Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. British Med Bullet 2006, 75/76:115-130.
48. Ho M, Siongok TK, Lyerly WH, Smith DH Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 1982, 76:741-747.
49. Coler RN, Carter D, Friede M, Reed SG Adjuvants for malaria vaccines. Parasit Immunol 2009, 31:520-528.
50. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Davis KE Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163:4481-4488.
51. Kamil AA, Khalil EAG, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, et al. Alum-precipitated autoclaved Leishmania major plus Bacilli Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans Roy Soc Trop Med Hyg 2003, 97:365-368.
52. Gicheru MM, Olobo JO, Anjili CO Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp Parasitol 1997, 85:109-116.
53. Herrera S, Fernandez OL, Vera O, Cardenas W, Ramirez O, Palacios R, et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg 2011, 84(Suppl 2):S12-S20.
54. Pierce MA, Ellis RD, Martin LB, sa Malkin E, eline Tierney E, Miura K, et al. Phase 1 safe and immunogenicity trial of the Plasmodium blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 2010, 28:2236-2242.
55. Gomez CE, Navea L, Lobaina L, Dubed M, Exposito N, Soto A, et al. The V3 loop based multiepitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates. Vaccine 1999, 17:2311-2319.